[其他期刊] PO-75 | Network meta-analysis comparing efficacy and safety outcomes of atogepant, rimegepant, and galcanezumab in patients with episodic migraine after including CHALLENGE-MIG Trial 求助已关闭
|
20
20
20
20
20
